Catalyst Wire Dossier Catalyst Wire Dossier

Fludarabine, Cyclophosphamide, and Ofatumumab chemoimmunotherapy

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Fludarabine, Cyclophosphamide, and Ofatumumab chemoimmunotherapy, covering 2020-10-14 to 2020-10-14. Get the full timeline:

Most recent: Clinical Trial Update: Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. [Phase 2]

See pricing